A concentration calculation describes what should be in a solution under its assumptions. A laboratory measurement asks what the analytical method actually detects. When those numbers disagree, the container deserves attention alongside the instrument and the calculation.
One possible explanation is adsorption: molecules attaching to a surface, such as a sample tube or vial wall. This differs from absorption into a material. A handling step that looks routine can therefore become a variable in an analytical experiment.
The useful question is specific: has recovery been evaluated for this molecule, in this container, under this method’s conditions?
What the experiments show
In a peer-reviewed laboratory study published on 1 May 2015, Kristensen and colleagues used analytical HPLC to examine three cationic peptides: mastoparan X, melittin and magainin 2. Recovery depended on container type and experimental conditions. Successive transfers through ordinary glass or polypropylene containers produced substantial losses in the tested systems; Protein LoBind tubes reduced losses under the conditions investigated.[1]
These were three particular peptides, not a test of every research peptide. The findings do not provide a loss percentage for an unrelated molecule, commercial vial or formulation.
A second analytical study, first published on 7 October 2020 and appearing in a 2021 journal issue, came from researchers at the Atlantic Cancer Research Institute and Mount Allison University in New Brunswick. Murphy and colleagues compared conventional and low-bind tubes and LC vials using the peptide Vn96 and two intact proteins. Low-bind containers improved the peptide’s analytical response, while the proteins required additional method-specific measures to obtain linear calibration.[2]
The contrast matters: an improvement for one analyte does not validate a handling approach for another. This study also did not address adsorption throughout every instrument component.
Three questions to keep separate
| Question | What it tells you | What it leaves open |
|---|---|---|
| What concentration was calculated? | The result of the stated mass and final-volume inputs | Whether those inputs describe the recoverable material |
| What amount was recovered or detected? | A result obtained through a particular analytical workflow | Whether loss, interference or other method effects explain a difference |
| Why did results differ? | A conclusion requiring controls and investigation | A weak signal alone does not identify its cause |
Adsorption is a possible explanation, not an automatic diagnosis. An unexpected signal should trigger a documented investigation rather than a conclusion about the original material.
A record that makes handling visible
For a laboratory team comparing results, “stored in a tube” is too vague. The following record is an editorial checklist, not a validated analytical protocol:
| Field | Record |
|---|---|
| Material | Sample identifier, molecule and available lot information |
| Containers | Manufacturer, product code, material and stated surface treatment |
| Solution | Composition, stated concentration and final volume |
| Contact history | Transfers, contact times and relevant temperature records |
| Analysis | Method version, calibration approach and measurement units |
| Controls | Applicable blanks and recovery checks defined by the laboratory |
| Result | Observations, uncertainty and unresolved explanations |
Consistent records help reveal differences between workflows. They do not eliminate the need for a fit-for-purpose method. A label such as “low-bind” is a reason to investigate suitability, not a substitute for evidence under the actual assay conditions.
Before changing a workflow, ask the analytical laboratory whether the proposed container or handling change requires a recovery comparison or further validation. Solvent and additive choices belong to that method assessment; this article supplies no preparation recipe.
The Canadian documentation context
Health Canada’s Guide to validation — drugs and supporting activities, published 29 June 2021, calls for analytical validation studies to follow an approved protocol and reach a clear conclusion in a report. Its scope is drug operations; it is cited here as a documentation reference, not a declaration that PEPTIVIA or a research laboratory meets its requirements.[3]
Analytical evidence and Canadian product authorization remain separate questions. Health Canada’s 9 April 2026 peptide advisory explicitly states that research-use labelling does not exempt products from regulatory requirements. A COA or recovery experiment likewise does not establish marketing authorization.[4]
For laboratory interpretation, the next step is a precise question to the laboratory: what evidence shows that this workflow measures this analyte reliably?
References
- Kristensen K, Henriksen JR, Andresen TL. Adsorption of Cationic Peptides to Solid Surfaces of Glass and Plastic. PLOS ONE. 2015;10(5):e0122419.
- Murphy EL, Joy AP, Ouellette RJ, Barnett DA. Improved intact peptide and protein quantitation by LC-MS: Battling the deleterious effects of analyte adsorption. Analytical Science Advances. 2021;2(5–6):299–307; first online 7 October 2020.
- Health Canada. Guide to validation — drugs and supporting activities (GUI-0029). 29 June 2021, section 8.2.
- Health Canada. Think twice before injecting peptides bought online: unauthorized products can seriously harm you. 9 April 2026.
Owner-provided references describe the studied materials and official guidance, not PEPTIVIA batches, product equivalence, safety or authorization. No independent expert review is claimed.
These references describe research and official guidance. They do not verify any PEPTIVIA batch, establish suitability for people, or authorize sale of a product in Canada.